Results 31 to 40 of about 15,511 (169)

Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects

Biomedicines, 2022
Type B adverse drug reactions (ADRs) represent a significant threat as their occurrence arises unpredictable and despite proper application of the drug.
Eline Gall, Florian Stieglitz, Andreas Pich, Georg Martin Norbert Behrens, Joachim Kuhn, Rainer Blasczyk, Funmilola Josephine Haukamp, Christina Bade-Döding   +7 more
doaj   +1 more source

Safety analysis of Ziagen® (abacavir sulfate) in postmarketing surveillance in Japan [PDF]

, 2014
Purpose: Abacavir is a nucleoside reverse transcriptase inhibitor indicated for human immunodeficiency virus (HIV) infection. In Japan, Ziagen® (300-mg abacavir sulfate) has been marketed since 1999.
Yoshifumi Kitazono, Kitaichi, Tomomi, Kitazono, Yoshifumi, Nagao, Takako, Kurita, Tomoko, Tomomi Kitaichi, Miura, Toshiyuki, Toshiyuki Miura, Takako Nagao, Tomoko Kurita   +9 more
core   +1 more source

Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan [PDF]

, 2014
Purpose: To obtain safety and effectiveness data on a combined anti-HIV drug, Epzicom (abacavir 600mg/lamivudine 300mg), a post-marketing surveillance on Epzicom that was required by the Japanese regulatory authority was conducted between January 2005 ...
Yoshifumi Kitazono, Kitaichi, Tomomi, Kitazono, Yoshifumi, Nagao, Takako, Kurita, Tomoko, Tomomi Kitaichi, Miura, Toshiyuki, Toshiyuki Miura, Takako Nagao, Tomoko Kurita   +9 more
core   +1 more source

Plasma pharmacokinetics of once-daily abacavir- and lamivudine-containing regimens and week 96 efficacy in HIV-infected Thai children

Journal of Virus Eradication, 2015
Background: Abacavir and lamivudine are approved for once-daily use in HIV-infected adults Limited pharmacokinetic (PK) data for abacavir and lamivudine in children are available.
Torsak Bunupuradah, Passorn Punyahotra, Tim R. Cressey, Amornrat Srimuan, Narukjaporn Thammajaruk, Jiratchaya Sophonphan, Chulalak Sriheara, David M. Burger, Thanyawee Puthanakit, Jintanat Ananworanich   +9 more
doaj   +1 more source

Abacavir use is associated with increased prothrombin conversion

Frontiers in Immunology, 2023
There is ongoing debate as to whether abacavir (ABC) increases the risk for cardiovascular disease(CVD) in people living with HIV (PLHIV) and the mechanisms underlying this possible association.
Qiuting Yan, Qiuting Yan, Shengshi Huang, Shengshi Huang, Wouter van der Heijden, Marisa Ninivaggi, Lisa van de Wijer, Romy de Laat-Kremers, Andre J. Van der Ven, Bas de Laat, Bas de Laat, Quirijn de Mast   +11 more
doaj   +1 more source

High-level cross-resistance to didanosine observed in South African children failing an abacavir- or stavudine-based 1st-line regimen.

PLoS ONE, 2014
BackgroundThe knowledge-base of emerging drug resistance profiles in children exposed to abacavir-based antiretroviral regimens in South Africa is very limited. This study investigated the suitability of didanosine-based 2nd-line regimens for children in
Kim Steegen, Leon Levin, Irene Ketseoglou, Michelle Bronze, Maria A Papathanasopoulos, Sergio Carmona, Wendy Stevens   +6 more
doaj   +1 more source

Evaluation of cardiovascular biomarkers In HIV-infected patients switching to abacavir or tenofovir based therapy

BMC Infectious Diseases, 2011
Background Our objective was to evaluate and compare the effect of abacavir on levels of biomarkers associated with cardiovascular risk. Methods In an open-label randomized trial, HIV-infected patients were randomized 1:1 to switch from zidovudine ...
Langdahl Bente L, Nielsen Ulla S, Frederiksen Christian A, Melchjorsen Jesper, Tolstrup Martin, Rasmussen Thomas A, Østergaard Lars, Laursen Alex L   +7 more
doaj   +1 more source

Tenofovir-induced quadriparesis

Journal of Dr. NTR University of Health Sciences, 2020
With an ever-increasing trend in the side effects of antiretroviral therapy (ART), usage of new regimens to decrease the mortality and morbidity has come into picture. Here we report a case of tenofovir-induced hypokalemic paralysis. A 60-year-old female
Ashalatha Muppur, J Mohan Sidhartha, Sd Allahuddin   +2 more
doaj   +1 more source

Genotyping for HLA Risk Alleles to Prevent Drug Hypersensitivity Reactions: Impact Analysis

Pharmaceuticals, 2021
Human Leukocyte Antigen (HLA) variants can be a risk factor for developing potentially fatal drug hypersensitivity reactions. Our aim was to estimate the potential impact of genotyping for the HLA risk alleles incorporated in the Dutch Pharmacogenetics ...
Lisanne E. N. Manson, Wilbert B. van den Hout, Henk-Jan Guchelaar   +2 more
doaj   +1 more source

Chemical and Toxicological Analysis of Antiretroviral Drugs

Разработка и регистрация лекарственных средств, 2019
Introduction. Human Immunodeficiency Virus (HIV) is one of the main socially significant infection all over the world. HIV-positive patients take medical care, including antiretroviral drugs (ARVs) pharmacotherapy.
T. N. Komarov, M. V. Belova, D. D. Stolyarova, I. E. Shohin, D. S. Bogdanova, O. A. Miskiv, Yu. V. Medvedev, I. M. Korenskaya   +7 more
doaj   +1 more source